U.S. Injectable Compounding Pharmacy Market, By Molecule, By Packaging Type, By Pharmacy Type

The U.S. injectable compounding pharmacy market is estimated to be valued at US$ 1,516.3 Mn in 2023 and is expected to exhibit a CAGR of 7.3% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 1,516.3 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	7.30%	2030 Value Projection:	US$ 2,477.4 Mn

Figure 1. U.S. Injectable Compounding Pharmacy Market Share (%), By Packaging Type, 2023

An injectable compounding pharmacy is a specialized healthcare facility that plays a critical role in customizing and preparing injectable medications to meet the unique needs of patients. Unlike traditional retail pharmacies, these compounding pharmacies have the expertise, equipment, and facilities to compound, or create sterile injectable medications from raw materials. This process involves combining, altering, or formulating drug ingredients to provide patients with personalized solutions at the time when standard and commercially available medications are not suitable. These pharmacies cater to a wide range of patients, including those with allergies, intolerances, or specific dosing requirements that cannot be met by mass-produced drugs. Injectable medications prepared in compounding pharmacies are used to treat various medical conditions, such as pain management, hormone therapy, fertility treatments, and intravenous nutrition. Injectable compounding pharmacies often collaborate closely with healthcare providers to develop tailored medication solutions. Their services are especially vital during drug shortages, emergencies, or when specific medications are unavailable, as they provide a lifeline for patients who require unique and customized treatment options. In short, injectable compounding pharmacies offers valuable resource for personalized medicines and thereby ensuring that the patients receive the most effective and safe injectable medications tailored to their specific needs.

Market Dynamics

The U.S. injectable compounding pharmacy market is set to grow due to supply chain resilience, and ongoing healthcare challenges of drug shortages, making it a vital component of the healthcare ecosystem. Further, the growing aging population is increasing the demand for personalized medications and this is expected to drive the compounding pharmacy. For instance, in May 2023, according to an article published by the United States Census Bureau in May 2023, 1 in every 6 people in the U.S. was aged 65 years or above in 2020. This older population is more vulnerable to chronic diseases and thus creating demand for injectable compounding pharmacy in U.S.

Key features of the study:

• The report provides an in-depth analysis of the U.S. injectable compounding pharmacy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for the market
• The study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. injectable compounding pharmacy market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of the study include Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd'S Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding Services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., SCA Pharma, Leiters Health, Medivant Healthcare and Vertisis Custom Pharmacy
• Insights from the report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• S. injectable compounding pharmacy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. injectable compounding pharmacy market

U.S. Injectable Compounding Pharmacy Market Detailed Segmentation:

• By Molecule:
  • Acetaminophen
  • Phenylephrine
  • Midazolam
  • Esmolol
  • Vancomycin
  • Epinephrine
  • Adenocaine
  • Fentanyl/Bupivacaine
  • Morphine
  • Amiodarone
  • Fentanyl
  • Heparin
  • Ketamine
  • Dextrose
  • Hydromorphone
  • Bupivacaine
  • Lidocaine
  • BKK (Bupivacaine, Ketorolac, Ketamine)
  • RCK (Ropivacaine, Clonidine, Ketorolac)
  • RKK (Ropivacaine, Ketorolac, Ketamine)
  • Norepinephrine
  • Diltiazem
  • Vasopressin
  • Others
• By Packaging Type:
  • Vials
  • Ampoules
  • Prefilled Syringes
  • Others
• By Pharmacy Type:
  • 503A Pharmacies
  • 503B Pharmacies
• Company Profiles
  • Central Admixture Pharmacy Services, Inc.
  • Nephron Pharmaceuticals Corporation
  • QuVa Pharma
  • Olympia Pharmacy
  • ASP Cares
  • Fagron Compounding Pharmacies
  • Athenex, Inc.
  • Avella Specialty Pharmacy
  • Atlas Pharmaceuticals
  • Empower Pharmacy
  • Carie Boyd'S Prescription Shop
  • Edge Pharma
  • Imprimis NJOF, LLC
  • IntegraDose Compounding Services, LLC
  • Wells Pharma of Houston, LLC
  • US Compounding Inc.
  • SCA Pharma
  • Leiters Health
  • Medivant Healthcare
  • Vertisis Custom Pharmacy